AREVA Med Presents Pharmacokinetics Data from Phase 1 Clinical Trial at SNMMI

May 16, 2013

Bethesda, MD, May 16, 2013

AREVA Med, an AREVA subsidiary specializing in the development of new innovative therapies to fight cancer, announced today that it will present pharmacokinetics data on the company's ongoing Phase 1 clinical trial of its alpha radioimmunotherapy 212Pb-TCMC-Trastuzumab in patients with intra-abdominal cancers. The data will be presented at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting in Vancouver, June 8-12, 2013. 

“We are pleased to report that the imaging dose of 212Pb-TCMCTrastuzumab has been administered to three ovarian cancer patients with abdominal metastasis,” said Ruby Meredith, M.D., Principal Investigator at University of Alabama.  "To date, 212Pb-TCMC-Trastuzumab has been well tolerated with no serious adverse events."

Phase 1 Clinical Trial Data

Data will be presented on three patients with HER-2- expressing ovarian cancer who had failed standard therapies. 212Pb-TCMC-Trastuzumab was administered intraperitoneally after 4mg/kg intravenous trastuzumab.

Objectives of the trial are safety, evaluation of plasma pharmacokinetics, human response, and anti-tumor effects. To date, six patients have been enrolled, and three of them have completed the six-month follow-up. After one year, the patients enter a period of long-term follow-up that includes quarterly visits for five years.


Orano Med Video

Click here to view the latest Orano Med Video


For more information about Orano Med, please contact:
Alison Tise
Tel.: + 1 (301) 841-1673